Big day, today! In addition to our HQ in Leiden, we are establishing our R&D hub in #Heidelberg. We look forward to joining the startup community fostered by BioLabs & BioRN Life Science Cluster Rhine-Neckar and to being close to DKFZ, EMBL and many more. bit.ly/2RXbQQl

We’re thrilled to welcome Joe Lewis as our SVP of Biology and Head of our R&D Hub in #Heidelberg. With over 20 years of experience in industry & academia most recently at EMBL, Joe expands our team of world-leading #phosphatase expertise. Welcome, Joe! bit.ly/3zNjBbM

We are #hiring! Following the decision to establish our R&D hub in #Heidelberg's new BioLabs facility, we are ramping up fast to grow our organization. Join us in one of three new positions: bit.ly/3iXBdfv #Careers in #drugdiscovery #CancerResearch

Today we welcome Charles McDermott as Chairman of our Board of Directors. His keen business insight & vast experience advancing biopharma companies will be vital as we further build our #phosphatase #drugdiscovery platform and expand our R&D capabilities. bit.ly/3Gv1LxF

Gerhard Müller, our CSO, is presenting at the Next Generation Kinase Inhibitors Summit on March 30. Catch his presentation at 4:30 p.m. ET to hear about how Anavo is developing approaches towards #phosphatase modulators for #drugdevelopment. bit.ly/37Xhf1w

We are happy to have joined BioLabs’ fully equipped lab space in BioLabs Heidelberg as we jump start our #drugdiscovery operations and unlock the full potential of phosphatase-targeted allosteric modulators. bit.ly/3seYApx

Gerhard Müller, our CSO, is excited to present on hit generation technologies for allosteric #phosphatase modulators at the Reversible Phosphorylation, Signal Integration and Drug Discovery EMBO Workshop on May 25. bit.ly/3MsRBRO

We are excited to participate in the BioLabs Heidelberg Life Science Investors’ Day on October 10, 2022 in #Heidelberg to talk about our work unlocking the full potential of #phosphatase target class. Come say hello if you will be there!

We are thrilled to announce the appointments of #phosphatase experts Dr Jukka Westermarck and Dr Anton Bennett to our Scientific Advisory Board. anavotx.com/#SAB

We are excited to attend #BIOEurope in person in Leipzig, Germany on October 24-26. Come say hello, we’d love to talk with you about our mission of unlocking the #phosphatase target class.

We have extended our seed funding to EUR 28M as we advance our pipeline of novel #phosphatase modulators toward the clinic. We are joined by MRL Ventures Fund, along with all existing investors: M Ventures, INKEF Capital, Taiho Ventures, bioqubeventures. bit.ly/3LwQj9g

Looking forward to #BioEquity in Dublin May 14-16. CEO Birgit Zech will share our mission and progress during our company presentation on May 16, and we’d love to chat with you about our approach to unlocking the #phosphatase target class. bit.ly/3HEslYu

We are proud to sponsor EMBO’s Signal Regulation by Protein Phosphatases workshop Aug 6-10. Stop by and say hi, and join Joe Lewis, our SVP Biology & Site Head Heidelberg, at his presentation on Aug 8. bit.ly/44tzDaK

We are thrilled to welcome Shaun McNulty as our new Chief Scientific Officer and Anna Quattropani as SVP Chemistry & Non-Clinical Development. anavotx.com/#leadership

Our team is looking forward to participating in the BioLabs Heidelberg Life Science Investors’ Day on September 28 in #Heidelberg. Stop by and say hello if you will be there! Learn more at anavotx.com

We are excited to attend #BIOEurope in Munich, Germany Nov 6-8. Stop by and say hello, we would love to discuss our mission of unlocking the full potential of the #phosphatase target class. Learn more about us at anavotx.com and register bit.ly/3Sm2CY8

We are honored to be finalists for the Seed-Stage Finance Raise of the Year at the 2023 LSX Leaders #lifestarsawards in London on November 13. Learn more at anavotx.com and bit.ly/3Mqtq8y

Today, we welcome Dr. Edward Holson as #CSO and President of Anavo US. With 25+ years of experience, Dr. Holson will lead our scientific strategy, advance the #IGNITE platform, and drive our mission to develop first-in-class phosphatase modulators.

Our CEO, Birgit Zech, & CSO, Edward Holson, will attend #BIOEurope2024 in Stockholm, Sweden, from Nov. 4-6. They’ll engage with key stakeholders to discuss our IGNITE platform and engage with fellow innovators. Connect with them via the event’s partnering system!